Irritable Bowel Syndrome Clinical Trial
— PERSUADEOfficial title:
Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery
Verified date | October 2018 |
Source | Maastricht University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Peppermint oil has shown to be effective in the treatment of Irritable Bowel Syndrome (IBS) symptoms in several meta-analyses. However, the level of evidence is moderate and peppermint oil remains relatively under-used in IBS. Therefore, the investigators will conduct a multicenter randomized, placebo controlled trial to investigate the effects of an eight-week peppermint oil treatment in IBS patients according to current European Medicines Agency (EMA) / US Food and Drug Administration (FDA) guidelines. To improve efficacy and to reduce side effects, the investigators aim to study the use of a new peppermint oil formulation, a colon-targeted-delivery capsule that will release the oil in the (ileo-) colonic region specifically.
Status | Completed |
Enrollment | 190 |
Est. completion date | October 1, 2018 |
Est. primary completion date | May 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Age between 18 and 75 years; 2. Diagnosed with Irritable Bowel Syndrome according to the Rome IV criteria: (Recurrent abdominal pain, at least 1 day/week for the last 3 months; Symptom onset at least 6 months prior to diagnosis; Associated with two or more of the following: 1. Pain related to defecation; 2. Pain associated with a change in frequency of stool; 3. Pain associated with a change in form (appearance/consistency) of stool 3. Based on the medical history and previous examination, no other causes for the abdominal complaints can be defined. Especially no history of: 1. Inflammatory Bowel Disease; 2. Celiac Disease; 3. Thyroid dysfunction (if not well-regulated). If alarm symptoms (including unexplained rectal blood loss or weight loss) are present, a colonoscopy has been performed and was negative for other causes. 4. Women in fertile age (<55 years old) must use contraception or be postmenopausal for at least two years. 5. Average worst abdominal pain score (on 11-point NRS) of > 3, during the two-week run-in period. Exclusion Criteria: 1. Insufficient fluency of the Dutch language; 2. Any previous use (also incidental use) of peppermint oil capsules in the last 3 months prior to inclusion (the use of peppermint tea, menthol candy etc. is allowed); 3. The inability to stop regular use of medication affecting the gastro-intestinal system (such as Non Steroidal Anti Inflammatory Drugs (NSAID), laxatives, prokinetics, opioids, smasmolytics and anti-diarrhoeal drugs). This use should be halted at least 1 week before enrollment into the run-in period; 1. The use of 1 antidepressant drug is allowed, providing dosing has been stable for > 6 weeks before enrollment; 2. The use of 1 proton pump inhibitor (PPI) is allowed, providing dosing has been stable > 6 weeks before enrollment; 4. Previous major abdominal surgery or radiotherapy interfering with gastrointestinal function: 1. Uncomplicated appendectomy, cholecystectomy and hysterectomy allowed unless within the past 6 months; 2. Other surgery upon judgment of the principle investigator; 5. History of liver disease, cholangitis, achlorhydria, gallstones or other diseases of the gallbladder/biliary system; 6. Pregnancy, lactation; 7. Using drugs of abuse; 8. Known allergic reaction to peppermint. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Gelderse Vallei Hospital | Ede | Gelderland |
Netherlands | Medical Center Leeuwarden | Leeuwarden | Friesland |
Netherlands | Alrijne Hospital | Leiden | Zuid Holland |
Netherlands | Maastricht University Medical Center | Maastricht |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1402-11. doi: 10.1097/MEG.0b013e3283405a17. Review. — View Citation
Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008 Nov 13;337:a2313. doi: 10.1136/bmj.a2313. Review. Erratum in: BMJ.2009;338:b1881. — View Citation
Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014 Jul;48(6):505-12. doi: 10.1097/MCG.0b013e3182a88357. Review. — View Citation
Maurer JM, Schellekens RC, van Rieke HM, Stellaard F, Wutzke KD, Buurman DJ, Dijkstra G, Woerdenbag HJ, Frijlink HW, Kosterink JG. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability. J Control Release. 2013 Dec 28;172(3):618-24. doi: 10.1016/j.jconrel.2013.09.021. Epub 2013 Oct 2. — View Citation
Schellekens RC, Stellaard F, Olsder GG, Woerdenbag HJ, Frijlink HW, Kosterink JG. Oral ileocolonic drug delivery by the colopulse-system: a bioavailability study in healthy volunteers. J Control Release. 2010 Sep 15;146(3):334-40. doi: 10.1016/j.jconrel.2010.05.028. Epub 2010 May 31. — View Citation
Weerts ZZRM, Keszthelyi D, Vork L, Aendekerk NCP, Frijlink HW, Brouwers JRBJ, Neef C, Jonkers DMAE, Masclee AAM. A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Adv Ther. 2018 Oct 4. doi: 10.1007/s12325-018-0802-1. [Epub ahead of print] — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Abdominal pain response rate after 8 weeks of treatment | A responder is defined as a patient who experiences at least a 30 percent decrease in the weekly average of worst daily abdominal pain (measured daily, on an 11 point NRS) compared to baseline weekly average in at least 50 percent of the weeks in which the treatment in given. | 8 weeks | |
Primary | Degree of relief response rate after 8 weeks of treatment. | A responder is defined as a patient who experiences a weekly relief of 1 or 2 (on a 7 point NRS) in at least 50 percent of the weeks in which treatment is given. | 8 weeks | |
Secondary | Global symptom improvement | As determined by IBS-SSS (IBS symptom severity scale) | 8 weeks | |
Secondary | Abdominal Discomfort | As determined by symptom diary | 8 weeks | |
Secondary | Bloating | As determined by IBS-SSS (IBS - symptom severity scale) | 8 weeks | |
Secondary | Regurgitation | As determined by symptom diary | 8 weeks | |
Secondary | Nausea | As determined by symptom diary | 8 weeks | |
Secondary | Urgency | As determined by symptom diary | 8 weeks | |
Secondary | Abdominal cramps | As determined by symptom diary | 8 weeks | |
Secondary | Average stool frequency and consistency | Measured by bristol stool chart | 8 weeks | |
Secondary | Indirect costs | Determined by Production Cost Questionnaire (PCQ) questionnaire | 8 weeks, 3 and 6 months | |
Secondary | Direct costs | Determined by Medical Cost Questionnaire (MCQ) questionnaire | 8 weeks, 3 and 6 months | |
Secondary | General Quality of Life | As determined by Euro-Qol-5D (EQ-5D) | 8 weeks, 3 and 6 months | |
Secondary | IBS related Quality of Life | As determined by IBS-Quality of life questionnaire (IBS-QoL) | 8 weeks, 3 and 6 months | |
Secondary | Use of Over the counter medication and rescue medication | Number of drugs taken as rescue medication (This is not an intervention) | 8 weeks | |
Secondary | Number and severity of side effects | Determined by daily diary | 8 weeks | |
Secondary | Responder rates following discontinuation of treatment at 3 and 6 months, different thresholds for the responder analysis of abdominal pain (e.g. 40 and 50 percent improvement); | 3 and 6 months after discontinuation of treatment | ||
Secondary | Responder rates when missing are interpreted as "no effect" | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |